CD8A and neoplasm: Technological advances in mass spectrometry and related methods have greatly enhanced our capacity to identify and map HLA-restricted tumor-associated antigens (TAAs) and neoantigen repertoires suitable as targets for CD8+ cytotoxic T lymphocyte (CTL)-mediated cancer immunotherapies.